ALKERMES | ALKS - SCHULD





SCHULD Veränderung Datum
AbbVie USD 67.5B 67.5B 2025-12
Acadia Pharmaceuticals USD 52.19M 2.62M 2025-12
ALKERMES USD 1.58B 1.51B 2026-03
Amgen USD 54.6B 17M 2025-12
Biogen USD 6.56B 275.1M 2026-03
BioMarin Pharmaceutical USD 1.44B 833.74M 2026-03
Bristol-Myers Squibb USD 47.14B 3.9B 2025-12
Coherus Biosciences USD 294.92M 1.25M 2025-03
Eli Lilly USD 42.5B 3.6M 2025-12
Gilead Sciences USD 24.94B 5M 2025-12
Heron Therapeutics USD 149.65M 157K 2024-09
Ionis Pharmaceuticals USD 2.34B 9.5M 2026-03
J&J USD 47.93B 2.14B 2025-12
Malin Corporation EUR 100K 0 2023-12
Merck USD 49.34B 7.97B 2025-12
Minerva Neurosciences USD 0 0 2024-09
Nektar Therapeutics USD 0 0 2022-06
Neurocrine Biosciences USD 406.2M 9.1M 2026-03
Otsuka Holdings JPY 227.98B 16.47B 2025-12
Ovoca Bio EUR 0 0 2021-06
Pfizer USD 63.73B 231M 2026-03
Regeneron Pharmaceuticals USD 2.71B 300K 2026-03
Vertex Pharmaceuticals USD 1.99B 44M 2026-03